Objective: To identify the genetic basis of a recessive syndrome characterized by prenatal hyperechogenic brain foci, congenital microcephaly, hypothalamic midbrain dysplasia, epilepsy, and profound global developmental disability.
intrauterine infection and the phenotype was not consistent with any known genetic syndrome that mimics congenital infection. We therefore undertook genome-wide analysis to determine the genetic cause of this microcephaly syndrome. METHODS Patients. Families were seen at the Medical Genetics and Pediatric Neurology clinics at Shaare Zedek Medical Center, Jerusalem, Israel.
Standard protocol approvals, registrations, and patient consent. Families were enrolled and blood or amniotic fluid samples were obtained after written consent. The study was approved by the Institutional Review Board of Shaare Zedek Medical Center and the Israel National Ethics Committee for Genetic Studies.
Genomic analyses. Genomic DNA was extracted from peripheral blood mononuclear cells or amniocytes. Whole exome sequencing 11 and homozygosity mapping 12 were performed as previously described.
Mutation and haplotype analyses were performed using primers listed in table e-1 on the Neurology ® Web site at Neurology.org. For evaluation of transcript expression, total RNA was extracted from peripheral blood leucocytes drawn into Tempus Blood RNA tubes (ABI, Chiba, Japan), then reverse-transcribed and converted to cDNA using random hexamers in the presence of RNase inhibitor (rRNasin; Promega, Madison, WI). A cDNA segment of PCDH12 exons 1 and 2 was amplified by PCR and Sanger sequenced.
TA cloning. Reverse transcription PCR products were cloned using the pGEM-T Easy Vector System (Promega) and transformed into JM109 high-efficiency competent cells (Promega). Blue/white color screening was used in order to select successful cloning of the insert. Selected clones were amplified with PCR Ready-Mix (Bio-Lab, Jerusalem, Israel) using T7 promoter primer and SP6 promoter primer (table e- Families and PCDH12 genotypes
Families with recessive congenital progressive microcephaly with prenatal perithalamic hyperechogenicity and hypothalamus-midbrain dysplasia. Genotypes of PCDH12 c.2515 C.T, p.R839X, are indicated below each sampled individual. PCDH12 c.2515C.T is homozygous in all affected individuals and segregates as expected for a recessive disease in all 4 families. TOP 5 termination of pregnancy.
families are from the same town of ;7,000 residents. In family A, index patient IV- At the first appointment with the index patient, her mother was in week 28 of a second pregnancy (IV-2). Prenatal ultrasound revealed microcephaly and hyperechogenic foci in the perithalamic and periventricular areas (figure 2, A.a-A.c). The parents chose to terminate the pregnancy and refused autopsy.
In family B, the oldest child (III-1), with symmetric intrauterine growth retardation (IUGR), significant periventricular hyperechogenicity, and suspected maternal CMV seroconversion (positive immunoglobulin G and immunoglobulin M), was initially suspected to have congenital infection. However, PCR for urine CMV and serology for Toxoplasma in blood and CSF were negative, and liver span, hepatic enzymes, and blood thrombocytes were normal. Brief clonic seizures began at age 4 days and evolved by age 8 months to multiple seizure types including infantile spasms. Metabolic workup (including lactate, pyruvate, pH, ammonia, aminoacids, and acylcarnitines in blood and urine organic acids) was normal. Chromosomal microarray analysis revealed no abnormalities. CSF lymphocyte count (2 cells/mL), aminoacids, and lactate were normal. The patient had severe microcephaly with no additional dysmorphism, severe visual impairment, dystonia, and profound developmental disability. Brain MRI revealed midbrainhypothalamus dysplasia similar to that found in family A (figure 2B.d). Based on marked clinical and imaging resemblance to the index case, and the shared geographic origin, we suspected that this child has the same syndrome observed in family A. The fetus of the fifth pregnancy in family B (III-5) was found in utero to have cranial hyperechogenic foci on prenatal sonography and negative toxoplasmosis, other (syphilis, varicella-zoster, parvovirus b19), rubella, cytomegalovirus, and herpes (TORCH) serology ( figure 2, B .a-B.c). The parents elected to terminate the pregnancy and refused autopsy, but consented to examination of the placenta, which revealed the placenta to be small (10th percentile) with vascular ectasia of the fetal blood vessels in the stem and intermediate villi. Family C was identified from a previous report 13 as likely having the same syndrome, and was found to originate from the same town as families A and B. Briefly, affected children in family C presented with congenital microcephaly, refractory epilepsy of neonatal onset, severe visual impairment, and profound global disability. The only surviving patient is III-2, now 26 years old. Her 4 older siblings died at ages 9, 3, 12, and 6 years from pulmonary aspiration. No DNA was available for the deceased children.
Family D was referred in pregnancy with IV-2 after visualization of perithalamic hyperechogenic foci and progressive symmetric IUGR (figure 2, C.a-C.c). At 24 weeks, microcephaly (21.6 SD) was noticed; at 26 weeks, reduced abdominal circumference (21.6 SD) emerged. TORCH serology was negative. The microcephaly progressed to 24.7 SD, and fetal MRI revealed the same midbrain-hypothalamus dysplasia described above ( Figure 2C .d). The parents elected to terminate the pregnancy and refused autopsy, but consented to pathology examination of the placenta, Table 1 Detailed clinical characteristics and imaging findings of patients which revealed the placenta to be small (5th percentile) without clear vascular pathology. All patients had fetal presentation of IUGR, microcephaly, and distinctive hyperechogenic foci in the perithalamic area (table 1, figure 2 ). Serology tests for intrauterine infections were normal for all. Postnatally, patients had neonatal seizures that became refractory to antiepileptic medications, profound global developmental disability, and severe visual impairment. Neurologic examinations revealed severe microcephaly with no other dysmorphism, axial hypotonia, and peripheral hypertonia (mostly dystonia). Brain MRI demonstrated unique midbrain dysplasia with undistinguished boundaries among the elongated midbrain, hypothalamus, and optic tracts. Chromosomal microarray analysis for genomic rearrangements and metabolic tests were normal.
Gene discovery. Whole exome sequencing of genomic DNA from patient IV-1 in family A (figure 1A) revealed 7 variants that were rare (,1% allele frequency in world populations), homozygous in the patient, and potentially functional (i.e., nonsense, frameshift, at a splice site, or altered a completely conserved aminoacid) (table e-2). These 7 variants were genotyped in the other affected and unaffected relatives of family A. Only one variant segregated with the disease in the family under a recessive model for inheritance of the microcephaly phenotype: Abbreviations: BLC-PMG 5 band-like intracranial calcification, simplified cerebral gyration, and polymicrogyria; CMV 5 cytomegalovirus; HDB-SC-CC 5 hemorrhagic destruction of the brain, subependymal, calcification, and congenital cataracts; IUGR 5 intrauterine growth retardation; PDA 5 patent ductus arteriosus; PFO 5 patent foramen ovale.
Next, PCDH12_R839X was genotyped in all participating relatives of families B, C, and D, none of whom had been evaluated by exome sequencing. Cosegregation of PCDH12_R839X with the syndrome perfectly fit a recessive model, with homozygosity for the mutation in all affected individuals and no unaffected individuals (figure 1). Given the allele frequency of 0.018 in the patients' hometown, the likelihood of this extent of cosegregation of genotype and phenotype by chance in families B, C, and D is 2.0 3 10 212 .
As an independent approach, genome-wide homozygosity mapping was carried out for 6 affected individuals and their 8 parents in the 4 families ( figure 3B ). Only one genomic region greater than 3 MB was homozygous in all 6 affected individuals and in none of the parents: a region of 11.7 MB on chromosome 5 from 129,673,384 to 141,354,220 (hg19; figure 2C ). This region harbors 220 genes (table e-3), including the entire chromosome 5 protocadherin cluster and hence PCDH12. To confirm that PCDH12_R839X was the only likely pathogenic variant in the shared 11.7 MB homozygous region, 25 short coding segments that were not covered by exome sequencing were individually evaluated by Sanger sequencing. No other candidate variants were identified. Analysis of microsatellites and single nucleotide polymorphisms in the 430 kb region immediately surrounding PCDH12 suggests that PCDH12_R839X has a common origin in all 4 families ( figure 3B ).
If translated, the PCDH12_R839X protein would be expected to lack most of the protocadherin cytoplasmic domain (figure e-1). However, the mutant transcript appears subject to nonsense-mediated decay. Sanger sequencing of cDNA from a heterozygote carrier revealed higher peak height for the wild-type vs mutant allele at the site of the mutation (figure 3D), and cloned cDNA from a heterozygous carrier yielded 88 wild-type and 14 mutant transcripts (p , 2.4 3 10 213 for deviation from the expected 1:1 ratio). DISCUSSION Congenital microcephaly with intracranial hyperechogenicity is associated primarily with congenital infection, particularly by CMV. However, several genetic disorders resemble congenital CMV infection (table 2). In 1984, Aicardi and Goutières 14 reported 8 children with familial progressive encephalopathy manifested by progressive microcephaly, spasticity, dystonia, basal ganglia calcifications, neonatal thrombocytopenia, and hepatomegaly. The clinical similarities between these children and those with congenital infections, and the observation in these children of chronic lymphocytosis in CSF, led to the discovery of increased CSF levels of the antiviral cytokine interferon-a in patients with AGS. 2 AGS is genetically heterogeneous. In patients with the syndrome, mutations in 7 genes have been identified to date: TREX1 (MIM 606609), RNASEH2B (MIM 610326), RNASEH2C (MIM 610330), RNASEH2A (MIM 606034), SAMHD1 (MIM 606754), ADAR (MIM 146920), and IHIF1 (MIM 606951). AGS is inherited as a recessive condition in all patients except those with mutations in TREX1. The function of all AGS genes is related to nucleic acid metabolism. 15 It appears that either host-mediated, as in the case of AGS, or virus-encoded nucleic acids signaling can induce overexpression of proinflammatory cytokines such as interferon-a that damage the developing brain. Among the clinical symptoms of AGS are development of recurrent (sterile) fever, chilblainlike skin lesions, and glaucoma, 15 none of which was found in our patients (tables 1 and 2). Cystic leukoencephalopathy due to RNASET2 mutations can also mimic congenital CMV infection. However, cystic leukoencephalopathy is not associated with severe progressive microcephaly. 16 PCDH12 is a member of the nonclustered protocadherin family of calcium-dependent cell adhesion proteins. Protocadherins are classified as clustered and nonclustered based on their genomic structure. More than 70 protocadherin proteins have been identified, most of which have been reported to play an important role in the regulation of brain development and function. [17] [18] [19] Several nonclustered PCDH genes have been implicated previously in neurologic disorders, including PCDH19 in female-restricted epilepsy and mental retardation, 20 PCDH15 in Usher syndrome type 1F, 21 PCDH21 in retinal degeneration, 22 PCDH8 in autism, 23 and PCDH7 in epilepsy. 24 PCDH12 promotes endothelial adhesion. 25, 26 Other disruptions of endothelial adhesion, due to mutations in occludin (OCLN) [5] [6] [7] or junctional adhesion molecule 3 (JAM3), 8, 9 lead to intracranial calcifications, severe and progressive congenital microcephaly, earlyonset seizures, and profound developmental disability. However, unlike patients with the PCDH12 mutation, patients with OCLN mutations also have underdeveloped cortex with bilateral polymicrogyria and patients with JAM3 mutations also have intracerebral hemorrhage with cystic destruction (tables 1 and 2).
In our patients, brain imaging illustrated distinctive characteristics: thick perithalamic hyperechogenicity on prenatal ultrasound and unique hypothalamic-midbrain dysplasia in prenatal and postnatal brain MRI (figure 2). Similar midbrain dysplasia has been reported previously in 6 patients with postnatal progressive microcephaly, but no information on prenatal imaging was available. 27 The nature of the hyperechogenic foci in our patients is distinctive. The foci do not cast an acoustic shadow as might be expected for calcifications of similar size; thus, they may possibly represent multiple tortuous vessels with multiple echographic interfaces. As PCDH12 expression is not limited to the perithalamic-midbrain brain area, the intriguing associations among PCDH12 mutations, perithalamic microangiopathy, hypothalamic-midbrain dysplasia, and profound microcephaly and brain impairment are yet to be discovered. [28] [29] [30] [31] Studies of the biological consequences of PCDH12 mutations may require use of cerebral organoids, rather than model organisms, as microcephaly syndromes are difficult to recapitulate in mice. 32 Indeed, mice null for PCDH12 demonstrate only mild vascular (primarily placental) deficit without clear neurologic involvement. 25, 26, 33 Similarly, mice null for TREX1, SAMHD1, IFIH1, or OCLN have neither structural nor functional neurologic deficits. 34, 35 A likely explanation for the lack of phenotypic correlation between the human disease and the corresponding murine knockouts is differing tissue specificity in expression patterns of the various protocadherins in mice and humans, 36 especially since precise spatial and temporal protocadherin expression is critical for vertebrate brain development. 28, 30, 37 In the mouse, PCDH12 is expressed almost exclusively in the placenta; its expression in brain is 500-fold lower than in placenta. In humans, PCDH12 is expressed at similar levels in many tissues, including brain and placenta (biogps.org). The same distinction holds for TREX1, IFIH1, and OCLN (but not SAMHD1); their relative expression in brain is much lower in mouse than in humans. Notably, the vascular pathology in the placenta demonstrated in PCDH12 knockout mice 26 may be reflected in the vascular ectasia of the fetal blood vessels of the placenta from fetus III-5 in family B.
Mutations leading to loss of function of protocadherins are implicated in other neurodevelopmental disorders, most notably PCDH19 mutations in female-restricted mental retardation and epilepsy. We add to these observations 4 families with a severely debilitating syndrome including congenital and progressive microcephaly with midbrain dysplasia and profound developmental disability due to a loss-of-function mutation in PCDH12. While it is formally possible that this syndrome is caused by a mutation that is not detectable by exome sequencing and that lies in a region of homozygosity less than 3 MB, cosegregation of homozygosity for the allele with the phenotype in 4 extended families and the loss of expression of the mutant PCDH12 transcript strongly, and independently, suggest that PCDH12 p.R839X is the causal allele. Identification of other patients with similar phenotypes and different mutations in PCDH12 would provide additional confirmation for these findings.
Finally, discovery of PCDH12 as a genetic basis for congenital microcephaly and intracranial hyperechogenic foci has practical clinical implications. In families with subsequently identified genetic causes for congenital microcephaly and intracranial calcifications, the first affected child was frequently misdiagnosed with congenital TORCH infections. Such misdiagnoses may result in familial recurrence of these devastating syndromes. Because each of these syndromes is rare, they are easily overlooked, but in the absence of serologic, molecular or epidemiologic evidence of infection, genetic causes of congenital microcephaly and intracranial calcifications are worthy of consideration. Given unique imaging findings in fetal sonography and brain MRI and a known genetic basis, this syndrome can be identified in utero. Mutations in PCDH12 also should be considered in unresolved cases of congenital microcephaly and intracranial calcifications. 10 
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